A carregar...
What Path Do We Take?
As existing biologics gain indications and new drugs make it to market, the array of choices makes it challenging to pick the right treatment for a given patient. Clinical effectiveness is the most important factor, but at the policy level, cost has to enter the discussion. Where?
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioCommunications LLC
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2706158/ https://ncbi.nlm.nih.gov/pubmed/22478710 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|